Log In Sign up
The largest database of trusted experimental protocols

Uprosertib

Manufactured by Selleck Chemicals
Visit Supplier
Sourced in United States

Uprosertib is a laboratory equipment product from Selleck Chemicals. It is a kinase inhibitor that targets the PI3K/AKT/mTOR signaling pathway.

Automatically generated - may contain errors

Lab products found in correlation

Tofacitinib, by Selleck Chemicals (1 mentions) Crenolanib, by Selleck Chemicals (1 mentions) At7867, by Selleck Chemicals (1 mentions) Otssp167, by Selleck Chemicals (1 mentions) Ipatasertib, by Selleck Chemicals (1 mentions) Human fc block, by Thermo Fisher Scientific (1 mentions) Unc2025, by Selleck Chemicals (1 mentions) Fixable viability dye efluor 506, by Thermo Fisher Scientific (1 mentions) Foxp3 transcription factor staining buffer set, by Thermo Fisher Scientific (1 mentions) Prednisolone, by Selleck Chemicals (1 mentions) Mk 2206, by Selleck Chemicals (1 mentions) Sch772984, by Selleck Chemicals (1 mentions) Fetal bovine serum (fbs), by Merck Group (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions) Lactic acid, by Merck Group (1 mentions)

3 protocols using uprosertib

1

RAJI Cell Lines Treatment Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
shCTL, shTRAF1, and shPKN1 RAJI cell lines, were seeded at 2 × 105 cells per well in a 48-well plate in complete media (RPMI 1640 with added 10% Fetal Calf Serum (FCS), 2-ME, glutamine, penicillin, streptomycin, and non-essential amino acids). Cells were harvested for flow cytometric analysis after 24 h of treatment with 0.1% DMSO control, PF-94122226 (link), UNC-2025 (Selleckchem, Houston, USA), crenolanib (Selleckchem), ipatasertib (Selleckchem), tofacitinib (Selleckchem), AT7867 (Selleckchem), uprosertib (Selleckchem), XL-228 (Chemietek, Indianapolis, USA), or OTSSP167 (Selleckchem), at various concentrations. All RAJI cells were treated with inhibitors in a final concentration of 0.1% DMSO in complete media. For analysis by flow cytometry, Fc receptors were blocked with human Fc Block (eBioscience). For surface staining, cells were stained with eBioscience Fixable Viability Dye eFluor® 506 and then fixed for intracellular staining with Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Purified TRAF1 antibody (clone 1F3, Serviceeinheit Monoklonale Antikörper; Institut für Molekulare Immunologie, Munich, Germany) was used prior to secondary staining with goat anti-rat PE (clone poly4054, Biolegend) for TRAF1.
Edilova M.I., Law J.C., Zangiabadi S., Ting K., Mbanwi A.N., Arruda A., Uehling D., Isaac M., Prakesch M., Al-awar R., Minden M.D., Abdul-Sater A.A, & Watts T.H. (2021). The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia. Oncoimmunology, 10(1), 1943234.
+ Open protocol
+ Expand
2

Compound Dissolution for Biological Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
Prednisolone, MK2206, Uprosertib and SCH772984 were purchased from Selleckchem (Munich, Germany) and dissolved as instructed by the manufacturer.
Butler M., Vervoort B.M., van Ingen Schenau D.S., Jongeneel L., van der Zwet J.C., Marke R., Meijerink J.P., Scheijen B., van der Meer L.T, & van Leeuwen F.N. (2022). Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways. Frontiers in Oncology, 12, 905665.
+ Open protocol
+ Expand
3

Cytotoxicity of Uprosertib Evaluated by SRB Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
To investigate the cytotoxic effects of uprosertib (Selleckchem, Houston, Texas, US) Sulforhodamine B (SRB) assays were performed according to manufacturer’s instructions.25 (link) Cells were plated into 96-well plates at a density of 4 × 104 cells per well and incubated for 24 h. Media were subsequently changed to DMEM (0 h) supplemented with glucose (5.6 mM), glutamine (2 mM), 10% FBS, lactic acid (0–20 mM; Sigma-Aldrich, St. Louis, Missouri, US) and uprosertib (0–15 μM) or vehicle (0.1% DMSO (Sigma-Aldrich, St. Louis, Missouri, US). Test media were replenished every 24 h to control for changes in extracellular metabolite concentrations. The SRB assay was performed at 0 and at 72 h post initial treatment. Data were presented as the Log2 of the optical density (OD; 565 nm) at 72 h relative to the OD at 0 h.
Barnes E.M., Xu Y., Benito A., Herendi L., Siskos A.P., Aboagye E.O., Nijhuis A, & Keun H.C. (2020). Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells. British Journal of Cancer, 122(9), 1298-1308.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!